COVID-19 Related Mortality and The BCG Vaccine
Paredes Mogica, J. A.; Nava, V.; Torres, J.
Show abstract
The coronavirus disease 2019 (COVID-19) pandemic has become a worldwide emergency. In the attempt to search for interventions that would improve outcomes, some studies have looked at the potential benefit of BCG vaccination. These past studies have found a statistically significant reduction in COVID-19 related mortality in countries with a current universal bacille Calmette-Guerin (BCG) vaccination policy. However, just as the authors themselves noted, the nature of ecological studies make them very prone to the presence of several confounders. This paper took into account demographic differences, economic differences and the different stages of the pandemic in each country; gathering data from publicly available sources. It was found that no statistically significant difference exists in mortality rates between countries with a current or prior BCG vaccination policy when compared to those that never had such a program. Nevertheless, the immunostimulatory potential of the BCG vaccine might still prove useful in the development of future vaccines or other prophylactic measures.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Excess respiratory, circulatory, neoplasm and other mortality rates during the Covid-19 pandemic in the EU and their implications 92%
- Covid-19 and excess mortality rates not comparable across countries 92%
- Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina 92%
Similar papers in this journal
- The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe 95%
- Public opinion on global distribution of COVID-19 vaccines: evidence from two nationally representative surveys in Germany and the United States 94%
- Modelling optimal vaccination strategies against Covid-19 in a context of Gamma variant predominance in Brazil 93%
Similar papers in this journal
- Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine – a prospective observational study 92%
- “Trained Immunity” from BCG Vaccination and Mycobacterium spp. Exposure may be Linked to Reduced Early Childhood (<5-Year-olds) Brain and CNS Cancer Incidences 92%
- Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.